An update from Telix Pharmaceuticals Ltd. ( (AU:TLX) ) is now available.
Telix Pharmaceuticals Limited announced the release of 237,669 ordinary shares from voluntary escrow, which were initially issued to the vendors of ARTMS Inc. as part of its acquisition. This release, scheduled for April 11, 2025, marks a significant step in integrating ARTMS into Telix’s operations, potentially enhancing its market positioning and offering new opportunities for stakeholders.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan. The company focuses on addressing significant unmet medical needs in oncology and rare diseases through its portfolio of clinical and commercial stage products.
YTD Price Performance: 15.37%
Average Trading Volume: 5,321
Technical Sentiment Signal: Sell
Current Market Cap: $5.63B
Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.